Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

The Potent STAT3/5 Inhibitor, BP-1-102 Demonstrates Significant Anti-Tumor Activity Against Waldenström Macroglobulinemia

Danielle C Croucher, Victor H Jimenez-Zepeda, MD, PD, Zhi Hua Li, Ellen Wei, Brent DG Page, James Turkson, Patrick T Gunning, Suzanne Trudel, MD, MSC, FRCPC

Blood (2011) 118 (21): 5101.

https://doi.org/10.1182/blood.V118.21.5101.5101

Published: 2011

Journal Articles

Studies of BP-1-102, a Novel Direct Small-Molecule Inhibitor of Stat3 Demonstrates Substantial Anti-Myeloma Pre-Clinical Activity

Victor H Jimenez-Zepeda, MD, PD, Zhi Hua Li, Brent DG Page, Seda Zeng, Ellen Wei, Chungyee Leung-Hagesteijn, James Turkson, Patrick T. Gunning, Suzanne Trudel, MD, MSC, FRCPC

Blood (2010) 116 (21): 138.

https://doi.org/10.1182/blood.V116.21.138.138

Published: 2010

Journal Articles

The HMGA1a-STAT3 axis: an “Achilles Heel” for Hematopoietic Malignancies Overexpressing HMGA1a?

Linda Resar, MD, Joelle Hillion, Ph.D., Surajit Dhara, Ph.D., Takita Felder Sumter, Ph.D., Mita Mukherjee, Ph.D., Francescopaolo Di Cello, Ph.D., Amy Belton, Ph.D., James Turkson, Ph.D., Souyma Jaganathan, Ph.D., Linzhao Cheng, Ph.D., Zhaohui Ye, B.S., Yingwei Lin, MD, PhD, Peter D. Aplan, MD, Richard Jove, Jeanne Kowalski, Kelsey Wertzler, B.S., Ray Reeves, Ph.D., Ossama Elbahlouh, M.D., Raka Bhattacharya, Ph.D.

Blood (2008) 112 (11): 3810.

https://doi.org/10.1182/blood.V112.11.3810.3810

Published: 2008

Journal Articles

STAT3: A Direct HMGA1 Gene Target Important in Lymphoid Malignancy.

Linda Resar, MD, Surajit Dhara, Ph.D., Takita Felder Sumter, Ph.D., Mita Mukherjee, Ph.D., James Turkson, Ph.D., Rich Jove, Ph.D., Ossama Elbahloul, M.D., Peter Aplan, M.D., Ying-Wei Lin, M.D., Ph.D., Raka Bhattacharya, Ph.D.

Blood (2006) 108 (11): 2222.

https://doi.org/10.1182/blood.V108.11.2222.2222

Published: 2006

Journal Articles

Disruption of STAT3 Signaling in Antigen Presenting Cells Represents a Novel Strategy To Overcome Tumor-Induced Antigen-Specific CD4+ T-Cell Tolerance.

Fengdong Cheng, M.D., Hongwei Wang, M.D., Alex G. Cuenca, Pedro Horna, M.D., Lldefonso Suarez, Jason Brayer, Ph.D., James Turkson, Ph.D., Richard Jove, Ph.D., Eduardo M. Sotomayor, M.D.

Blood (2004) 104 (11): 109.

https://doi.org/10.1182/blood.V104.11.109.109

Published: 2004

NARROW

The Potent STAT3/5 Inhibitor, BP-1-102 Demonstrates Significant Anti-Tumor Activity Against Waldenström Macroglobulinemia

Studies of BP-1-102, a Novel Direct Small-Molecule Inhibitor of Stat3 Demonstrates Substantial Anti-Myeloma Pre-Clinical Activity

The HMGA1a-STAT3 axis: an “Achilles Heel” for Hematopoietic Malignancies Overexpressing HMGA1a?

STAT3: A Direct HMGA1 Gene Target Important in Lymphoid Malignancy.

Disruption of STAT3 Signaling in Antigen Presenting Cells Represents a Novel Strategy To Overcome Tumor-Induced Antigen-Specific CD4+ T-Cell Tolerance.

Email alerts

ASH Publications

American Society of Hematology

The Potent STAT3/5 Inhibitor, BP-1-102 Demonstrates Significant Anti-Tumor Activity Against Waldenström Macroglobulinemia

Studies of BP-1-102, a Novel Direct Small-Molecule Inhibitor of Stat3 Demonstrates Substantial Anti-Myeloma Pre-Clinical Activity

The HMGA1a-STAT3 axis: an “Achilles Heel” for Hematopoietic Malignancies Overexpressing HMGA1a?

STAT3: A Direct HMGA1 Gene Target Important in Lymphoid Malignancy.

Disruption of STAT3 Signaling in Antigen Presenting Cells Represents a Novel Strategy To Overcome Tumor-Induced Antigen-Specific CD4+ T-Cell Tolerance.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only